Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAMPEDE2: multi-arm trial in metastatic hormone-sensitive prostate cancer
2025-522145-21-00Phase 3Authorised
- Sponsor
- University College London
- Start
- Feb 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised trial in prostate cancer (PCa) comparing ADT alone (standard of care control) with ADT + Pluvicto (2 arms). Primary endpoint: Overall survival. Planned start Feb 2026; status: authorised.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2025-522145-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522145-21-00.